Weekly Trend Brief2026 W46

GLP-1 Eye Side Effect Warnings Spread, Controversy From Day One of Overseas Imports

This was a week where safety warnings and price controversies around GLP-1 obesity drugs broke out at the same time. The Ministry of Food and Drug Safety (MFDS) officially issued wording about vision damage risk, and on the same day, personal imports of overseas prescription drugs took effect, stirring up controversy over price gaps and safety management blind spots. Meanwhile, in the protein and blood-sugar-management health functional food market, competition among large companies for new products intensified.

Cover illustration for this week's brief

01Top 5 this week

  1. MFDS distributes safety letter on vision damage risk across the entire GLP-1 class

    In plain words Official guidance has now come out in Korea too, saying that if your vision gets worse while using GLP-1 drugs like semaglutide (Wegovy) or tirzepatide (Mounjaro), you should stop taking the drug right away.

    • The MFDS distributed a safety letter on vision damage risk covering the entire GLP-1 class
    • This follows the US FDA's move to make warning labels mandatory
    • Patients were advised to stop medication immediately if vision abnormalities are suspected

    Why it matters

    This is safety information that anyone using or considering GLP-1 drugs should know. However, according to reports, the incidence rate is relatively rare, at 6.4 cases per 100,000 person-years.

    Sources청년의사뉴스토마토전자신문메디칼업저버

    Illustration: MFDS distributes safety letter on vision damage risk across the entire GLP-1 class
  2. First day of personal imports of overseas prescription drugs: Japan 'Sushi-Jaro' trips and price gap controversy

    In plain words People can now bring in up to a 3-month supply of semaglutide (Wegovy) or tirzepatide (Mounjaro) prescribed overseas. Reports noted that since prescription prices in Japan are 1/3 to 1/5 of those in Korea, demand for buying trips to Japan is rising.

    • MFDS and the Korea Customs Service allowed personal imports of up to a 3-month supply of overseas-prescribed GLP-1 drugs
    • Reports say prescription prices in Japan are about 1/3 to 1/5 of Korea's prices
    • The National Assembly pointed out concerns about repeated imports and gaps in safety management

    Why it matters

    Because of the large price gap, informal routes like overseas prescription trips may increase, and there are concerns this could create a management blind spot.

    Sources뉴시스비즈니스포스트OBC 뉴스투데이신문

  3. Cheong Kwan Jang's 'GLPro' and Daesang Wellife's blood-sugar-management shakes heat up health functional food competition

    In plain words Major health functional food companies are rolling out new products one after another that emphasize blood sugar management and fiber/protein content.

    • Cheong Kwan Jang promoted its 'GLPro' line by citing a population of 17.42 million people managing blood sugar (company announcement)
    • Daesang Wellife launched two blood-sugar-management shakes containing 8.6g of fiber and 21g of protein

    Why it matters

    For consumers choosing blood-sugar-management health functional foods, this is a good chance to compare ingredient content and prices.

    Sources메가경제푸드투데이

  4. Pulmuone launches 'Design Meal Protein Solution,' Vazio ranks No. 1 in food at Olive Young

    In plain words Pulmuone released a new protein meal-replacement product, and the new brand Vazio rose to No. 1 in the food category at Olive Young.

    • Pulmuone launched two 'Design Meal Protein Solution' products
    • Vazio's protein shake ranked No. 1 in Olive Young's food category

    Why it matters

    Consumers looking for protein meal replacements now have more options. New brands are also standing out in offline channels.

    Sources월간포장이투뉴스

    Illustration: Pulmuone launches 'Design Meal Protein Solution,' Vazio ranks No. 1 in food at Olive Young
  5. Survey finds GLP-1 users seek 'small portions, packed with nutrition' foods

    In plain words A survey found that since GLP-1 drugs reduce meal portions, users look for foods packed with protein and fiber in just a bite or two. However, labeling something as 'GLP-1-specific' reportedly makes consumers suspicious instead.

    • Muscle maintenance, gut health, and fiber were cited as important factors
    • Taste, small-portion packaging, and trustworthy nutrition labeling were identified as key
    • The research was sponsored by flavor company Givaudan, so it should be considered with that in mind

    Why it matters

    This is a trend worth noting for consumers looking for small, high-nutrition foods, whether or not they use GLP-1 drugs.

    SourcesNutraIngredients

    Illustration: Survey finds GLP-1 users seek 'small portions, packed with nutrition' foods

Links go to the original articles; titles are in their original language.

02By topic

GLP-1
Warnings about vision damage (optic neuropathy) from GLP-1 drugs were officially issued by both the MFDS and the FDA, and as personal imports of overseas prescription drugs took effect, the 'Sushi-Jaro' trend of prescription trips to Japan and price controversy grew. Reports also continued to stress concerns about muscle loss and the importance of protein intake.
Protein
Competition between major companies and new brands is intensifying in the protein drink and shake market. Pulmuone's new product, Vazio's No. 1 ranking at Olive Young, and Take-Fit's sales growth stood out, while globally, diversification continued with clear protein and protein coffee formats.
Supplements & brands
Alongside new blood-sugar-management shake launches, a McKinsey survey found that consumers are demanding stronger evidence for health functional foods. Some products were recalled after failing quality inspections.
Regulation & safety
The MFDS distributed a safety letter on vision damage risk covering the entire GLP-1 class, and as the personal import system for overseas prescription drugs took effect, the National Assembly pointed out gaps in follow-up management. There was also news of a crackdown on false patent claims for health foods.

03Glossary

Optic neuropathy
A condition where problems with blood flow to the eye can damage vision.
Semaglutide (Wegovy)
An ingredient that reduces appetite to help with weight loss, sold under the brand name Wegovy.
Tirzepatide (Mounjaro)
An obesity/diabetes treatment ingredient that works similarly to semaglutide.
Halo effect
A term referring to consumers who change their eating habits like GLP-1 users even though they don't use the drugs.
Clear protein
A protein drink made in a clear form rather than a cloudy, milk-like one.

04What to watch next week

  • It's worth watching how the MFDS's review of label changes for the GLP-1 class (reflecting possible blindness risk) gets finalized after next week.
  • It's worth watching whether the National Assembly and MFDS take further supplementary measures regarding the personal import system for overseas prescription drugs.
  • It's worth watching whether demand for 'Sushi-Jaro' prescription trips to Japan keeps rising, and how hospitals in Japan respond.

This brief summarises public news reports for general information. It is not medical advice. Please talk to a healthcare professional about medicines or health concerns.